{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T20:46:14Z","timestamp":1792097174955,"version":"4.4.0"},"reference-count":28,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T00:00:00Z","timestamp":1776297600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Immunol."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Immune checkpoint inhibitors (ICIs) have revolutionized cancer therapy, yet treatment responses remain heterogeneous. With the widespread implementation of coronavirus disease 2019 (COVID-19) vaccination, uncertainty persists regarding its impact on antitumor efficacy in patients receiving ICIs. While vaccine safety has been extensively studied, the association between COVID-19 vaccination and ICI therapeutic outcomes has not been systematically evaluated.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We conducted a systematic review and meta-analysis of observational studies examining the association between COVID-19 vaccination and oncologic outcomes in patients treated with ICIs. PubMed, Embase, and Scopus were searched from 2020 to December 31, 2025. Primary outcomes were overall survival (OS) and progression-free survival (PFS); secondary outcomes included objective response rate (ORR) and disease control rate (DCR). Hazard ratios (HRs) and odds ratios (ORs) with 95% confidence intervals (CIs) were pooled using random-effects models.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Ten observational studies comprising 4,929 patients receiving ICIs were included. COVID-19 vaccination was associated with significantly improved PFS (pooled HR\u00a0=\u00a00.66, 95% CI 0.48\u20130.90) and OS (pooled HR\u00a0=\u00a00.51, 95% CI 0.39\u20130.66) compared with no vaccination. Vaccinated patients showed numerically higher ORR (pooled OR\u00a0=\u00a01.74, 95% CI 0.89\u20133.41) and DCR (pooled OR\u00a0=\u00a01.74, 95% CI 0.83\u20133.46), although these differences were not statistically significant. Subgroup analyses by vaccine platform and cancer type yielded consistent associations.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>COVID-19 vaccination is associated with improved survival outcomes in patients receiving ICIs. Although the observational nature of available data warrants cautious interpretation, the consistency of findings and their biological plausibility support the clinical compatibility of vaccination with ICI therapy, but causal or synergistic effects cannot be established from these data. These results reinforce current vaccination recommendations and highlight the need for prospective studies to further elucidate underlying mechanisms and optimize integration with cancer immunotherapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Systematic review registration<\/jats:title>\n                    <jats:p>\n                      <jats:ext-link>https:\/\/www.crd.york.ac.uk\/prospero\/<\/jats:ext-link>\n                      , identifier CRD420261277938.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fimmu.2026.1807267","type":"journal-article","created":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:25:32Z","timestamp":1776317132000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["COVID-19 vaccination and clinical outcomes of immune checkpoint inhibitors therapy in cancer patients: a meta-analysis of real-world studies"],"prefix":"10.3389","volume":"17","author":[{"given":"Hongyan","family":"Xi","sequence":"first","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine","place":["Yancheng, Jiangsu, China"]},{"name":"Department of Obstetrics and Gynecology, Yancheng TCM Hospital","place":["Yancheng, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meichao","family":"Li","sequence":"additional","affiliation":[{"name":"Department of Integrated Traditional Chinese and Western Medicine, Liuzhou People\u2019s Hospital","place":["Liuzhou, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinhai","family":"Shen","sequence":"additional","affiliation":[{"name":"State Key Laboratory of Natural Medicines, China Pharmaceutical University","place":["Nanjing, Jiangsu, China"]},{"name":"Center for New Drug Safety Evaluation and Research, China Pharmaceutical University","place":["Nanjing, Jiangsu, China"]},{"name":"School of Basic Medicine and Clinical Pharmacy, China Pharmaceutical University","place":["Nanjing, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxuan","family":"Lin","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Guangxi Hospital Division of The First Affiliated Hospital, Sun Yat-sen University","place":["Nanning, Guangxi, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beibei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine","place":["Yancheng, Jiangsu, China"]},{"name":"Department of Obstetrics and Gynecology, Yancheng TCM Hospital","place":["Yancheng, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingyun","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine","place":["Yancheng, Jiangsu, China"]},{"name":"Department of Obstetrics and Gynecology, Yancheng TCM Hospital","place":["Yancheng, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongmei","family":"Wang","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine","place":["Yancheng, Jiangsu, China"]},{"name":"Department of Obstetrics and Gynecology, Yancheng TCM Hospital","place":["Yancheng, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuxin","family":"Zhao","sequence":"additional","affiliation":[{"name":"Department of Obstetrics and Gynecology, Yancheng TCM Hospital Affiliated to Nanjing University of Chinese Medicine","place":["Yancheng, Jiangsu, China"]},{"name":"Department of Obstetrics and Gynecology, Yancheng TCM Hospital","place":["Yancheng, Jiangsu, China"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,16]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1507977","article-title":"Efficacy and safety of adding immune checkpoint inhibitors to first-line standard therapy for recurrent or advanced cervical cancer: a meta-analysis of phase 3 clinical trials","volume":"15","author":"Zhang","year":"2024","journal-title":"Front Immunol"},{"key":"B2","doi-asserted-by":"publisher","DOI":"10.1016\/j.clon.2025.103783","article-title":"Efficacy and safety of immunochemotherapy in advanced triple-negative breast cancer: a meta-analysis of randomised clinical trials","volume":"40","author":"Shen","year":"2025","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"B3","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1564604","article-title":"First-line immune checkpoint inhibitors with chemotherapy in advanced gastric and gastroesophageal junction adenocarcinoma: a meta-analysis of phase 3 trials","volume":"16","author":"Lin","year":"2025","journal-title":"Front Immunol"},{"key":"B4","doi-asserted-by":"publisher","first-page":"1579","DOI":"10.1186\/s12885-025-15039-2","article-title":"Combination of immunotherapy and chemotherapy as first-line treatment for advanced or recurrent endometrial cancer: a meta-analysis of phase 3 trials","volume":"25","author":"Li","year":"2025","journal-title":"BMC Cancer"},{"key":"B5","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1667793","article-title":"First-line immune checkpoint inhibitors plus targeted therapy versus sorafenib or lenvatinib monotherapy for unresectable or advanced hepatocellular carcinoma: a meta-analysis of phase 3 trials","volume":"16","author":"Lin","year":"2025","journal-title":"Front Immunol"},{"key":"B6","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2021.09.020","article-title":"Hallmarks of response, resistance, and toxicity to immune checkpoint blockade","volume":"184","author":"Morad","year":"2021","journal-title":"Cell"},{"key":"B7","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.12.006","article-title":"COVID-19 vaccination and breakthrough infections in patients with cancer","volume":"33","author":"Schmidt","year":"2022","journal-title":"Ann Oncol"},{"key":"B8","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00578-z","article-title":"Immunological mechanisms of vaccine-induced protection against COVID-19 in humans","volume":"21","author":"Sadarangani","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat Rev Immunol"},{"key":"B10","doi-asserted-by":"publisher","first-page":"e006246","DOI":"10.1136\/jitc-2022-006246","article-title":"COVID-19 vaccination in patients with cancer receiving immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"11","author":"Ruiz","year":"2023","journal-title":"J Immunother Cancer"},{"key":"B11","doi-asserted-by":"publisher","DOI":"10.1002\/rmv.2495","article-title":"Serological response and immune-related adverse events following COVID-19 vaccination in cancer patients treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"34","author":"Wang","year":"2024","journal-title":"Rev Med Virol"},{"key":"B12","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2025.2539593","article-title":"Effects of COVID-19 vaccination on irAEs and prognosis in lung cancer patients receive PD-(L)1 inhibitors","volume":"21","author":"Luo","year":"2025","journal-title":"Hum Vaccin Immunother"},{"key":"B13","doi-asserted-by":"publisher","first-page":"e004157","DOI":"10.1136\/jitc-2021-004157","article-title":"Impact of COVID-19 vaccination on the use of PD-1 inhibitor in treating patients with cancer: a real-world study","volume":"10","author":"Mei","year":"2022","journal-title":"J\u00a0Immunother Cancer"},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-09655-y","article-title":"SARS-CoV-2 mRNA vaccines sensitize tumours to immune checkpoint blockade","volume":"647","author":"Grippin","year":"2025","journal-title":"Nature"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1948","DOI":"10.3390\/cancers17121948","article-title":"Periodic boosters of COVID-19 vaccines do not affect the safety and efficacy of immune checkpoint inhibitors for advanced non-small cell lung cancer: a longitudinal analysis of the Vax-On-Third Study","volume":"17","author":"Fabbri","year":"2025","journal-title":"Cancers (Basel)"},{"key":"B16","doi-asserted-by":"publisher","first-page":"n71","DOI":"10.31222\/osf.io\/v7gm2","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"B17","doi-asserted-by":"publisher","DOI":"10.1007\/s10654-010-9491-z","article-title":"Critical evaluation of the Newcastle-Ottawa scale for the assessment of the quality of nonrandomized studies in meta-analyses","volume":"25","author":"Stang","year":"2010","journal-title":"Eur J Epidemiol"},{"key":"B18","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1186\/s13643-025-02752-z","article-title":"Practical methods for incorporating summary time-to-event data into meta-analysis: updated guidance","volume":"14","author":"Tierney","year":"2025","journal-title":"Syst Rev"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.14740\/wjon1620","article-title":"The effect of mRNA-based COVID-19 vaccination on anti-programmed cell death protein 1 blockade for nasopharyngeal cancer may differ from a virus-inactivated vaccine","volume":"14","author":"Hayashi","year":"2023","journal-title":"World J Oncol"},{"key":"B20","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2022.10.002","article-title":"Potentially improved response of COVID-19 vaccinated nasopharyngeal cancer patients to combination therapy with anti-PD-1 blockade and chemotherapy","volume":"34","author":"Hua","year":"2023","journal-title":"Ann Oncol"},{"key":"B21","doi-asserted-by":"publisher","DOI":"10.1200\/jco.2023.41.16_suppl.e14696","article-title":"Clinical outcomes in patients with metastatic non-small cell lung cancer and head and neck squamous cell cancer treated with immune checkpoint inhibitors according to COVID-19 vaccination status","volume":"41","author":"Khaddour","year":"2023","journal-title":"J Clin Oncol"},{"key":"B22","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1186\/s13027-023-00526-7","article-title":"COVID-19 vaccination is associated with enhanced efficacy of anti-PD-(L)1 immunotherapy in advanced NSCLC patients: a real-world study","volume":"18","author":"Qian","year":"2023","journal-title":"Infect Agent Cancer"},{"key":"B23","doi-asserted-by":"publisher","DOI":"10.1080\/21645515.2024.2358575","article-title":"Patients with advanced cancer were treated with immune checkpoint inhibitors and injected with COVID-19 vaccine to improve their prognosis without increasing pancreatic related adverse events","volume":"20","author":"Li","year":"2024","journal-title":"Hum Vaccin Immunother"},{"key":"B24","doi-asserted-by":"publisher","first-page":"11151","DOI":"10.1200\/jco.2025.43.16_suppl.11151","article-title":"Association of co-administration of a vaccine with immune checkpoint inhibitors with survival","volume":"43","author":"Wang","year":"2025","journal-title":"J Clin Oncol"},{"key":"B25","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2814-7","article-title":"COVID-19 vaccine BNT162b1 elicits human antibody and T(H)1 T cell responses","volume":"586","author":"Sahin","year":"2020","journal-title":"Nature"},{"key":"B26","doi-asserted-by":"publisher","first-page":"1993","DOI":"10.1016\/j.immuni.2022.10.014","article-title":"Innate immune mechanisms of mRNA vaccines","volume":"55","author":"Verbeke","year":"2022","journal-title":"Immunity"},{"key":"B27","doi-asserted-by":"publisher","first-page":"86","DOI":"10.3390\/vaccines10010086","article-title":"Safety and immunogenicity of the third booster dose with inactivated, viral vector, and mRNA COVID-19 vaccines in fully immunized healthy adults with inactivated vaccine","volume":"10","author":"Kanokudom","year":"2022","journal-title":"Vaccines (Basel)"},{"key":"B28","first-page":"2025.11.03.25339367","article-title":"Avoiding biases when estimating effects of COVID-19 vaccination during immune checkpoint inhibitor therapy","volume-title":"medRxiv","author":"Dumas","year":"2025"}],"container-title":["Frontiers in Immunology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1807267\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T05:25:33Z","timestamp":1776317133000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fimmu.2026.1807267\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,16]]},"references-count":28,"alternative-id":["10.3389\/fimmu.2026.1807267"],"URL":"https:\/\/doi.org\/10.3389\/fimmu.2026.1807267","relation":{},"ISSN":["1664-3224"],"issn-type":[{"value":"1664-3224","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,16]]},"article-number":"1807267"}}